Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · LAURUSLABS

LAURUSLABS

HealthcarePharmaceuticals & Biotechnology₹125461 cr market cap
₹2306.00 ▼ -0.71% today As of 19 Nov 2026
52-week low ₹930.2052-week high ₹2454.00

-5.4% from the 52-week high · +149.7% above the low

Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The company is headquartered in Hyderabad, Telangana and currently employs 5,753 full-time employees. The company went IPO on 2016-12-19. The firm offers integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. The firm operates through three segments: Laurus Generics, Laurus Synthesis, and Laurus Bio. The Laurus Generics segment comprises API and FDF-Development, manufacture and sale of APIs and advanced intermediates and oral solid formulations/FDF. Laurus Synthesis segment comprises key starting materials (KSM), intermediates and APIs for new chemical entities (NCEs). Laurus Bio segment comprises recombinant products, animal origin free products for safer and viral free bio manufacturing. The firm operates through two geographical segments: Revenue from customers within India-Domestic, and Revenue from customers outside India-Exports. The firm sell its APIs in 56 countries.

The short version. LAURUSLABS reported revenue of ₹2,206 crore for Sep 2026, up 33.5% from a year earlier. Net profit was ₹441 crore (up 126.2% year on year). Return on equity was 16.8% in Mar 2026. Promoter holding was 27.47% in Sep 2026, down 0.15 points over 8 quarters.

1 · The price

How has the stock traded?

LAURUSLABS trades 5.4% below its 52-week high and 149.7% above its 52-week low.

Change over period: —

1M+12.3%
3M+28.9%
6M+70.6%
1Y+130.7%

2 · The business

Is it growing?

Sales, year on year+33.5%

Sep 2026 revenue of ₹2,206 cr.

Profit, year on year+126.2%

Sep 2026 net profit of ₹441 cr.

Net margin20.0%

8.2 pts higher than a year earlier.

3-year growth4.0% profit

Revenue compounded at 4.3% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue22062026181217781653157017201415
Net profit44136827925219516323492
Net margin %20.018.115.414.211.810.413.66.5
EPS (₹)8.176.85.174.663.613.024.331.71

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue68135554504160414936481428322292
Net profit88935816179082898425594
Net margin %13.06.53.213.116.820.49.04.1
EPS (₹)16.466.642.9814.6715.418.334.781.76

3 · The quality

How well does it turn capital into profit?

Return on equity was 16.8% in Mar 2026; debt to equity is 0.45.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %16.88.03.919.6
Return on capital %19.712.18.024.4
EBITDA margin %26.720.115.926.4
Net margin %12.96.43.213.1

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR4.3%7.3%
Profit CAGR4.0%-2.0%
Debt to equity0.45
Interest cover7.9x
Current ratio1.33
P/E ratio94.2

4 · The owners

Who holds it, and are they adding?

Promoter holding27.47%

Down 0.15 pts over 8 quarters.

Foreign institutions30.84%

Up 5.28 pts over 8 quarters.

Domestic institutions11.86%

Down 0.88 pts over 8 quarters.

Mutual fund schemes233

+54 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter27.6227.6227.5927.5927.4927.4927.4727.47-0.15
FII25.5625.5225.726.1626.5225.8228.030.84+5.28
DII12.7411.7711.9411.7312.4313.9713.7411.86-0.88
Public34.0835.0934.7734.5133.5632.7130.7829.83-4.25

Mutual fund holdings · Oct 2026

233 schemes hold this stock

179 the month before.

  • TATA NIFTY MIDSMALL HEALTHCARE INDEX FUND14.12% of NAV
  • Motilal Oswal Nifty MidSmall Healthcare Index Fund14.09% of NAV
  • SAMCO LARGE & MID CAP FUND10.27% of NAV
  • ICICI Prudential Nifty Pharma ETF9.27% of NAV
  • Nippon India Nifty Pharma ETF9.26% of NAV
  • ICICI Prudential Nifty Pharma Index Fund9.26% of NAV
  • TATA NIFTY MIDCAP 150 MOMENTUM 50 INDEX FUND8.73% of NAV
  • SBI Nifty Midcap 150 Momentum 50 ETF8.72% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for LAURUSLABS are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about LAURUSLABS

What is the LAURUSLABS share price?

LAURUSLABS (LAURUSLABS) last closed at ₹2,306.00, down 0.71% on the day. Its 52-week range is ₹930.20 to ₹2,454.00.

What is the market cap of LAURUSLABS?

LAURUSLABS has a market capitalisation of about ₹125,461 crore. Its price-to-earnings ratio is 94.2.

How are LAURUSLABS's latest results?

LAURUSLABS reported revenue of ₹2,206 crore for Sep 2026, up 33.5% from a year earlier. Net profit was ₹441 crore (up 126.2% year on year). Return on equity was 16.8% in Mar 2026. Promoter holding was 27.47% in Sep 2026, down 0.15 points over 8 quarters.

Who owns LAURUSLABS?

As of Sep 2026, shareholding was: Promoter 27.47%, FII 30.84%, DII 11.86%, Public 29.83%.

How many mutual funds hold LAURUSLABS?

233 mutual fund schemes held LAURUSLABS in October 2026. That compares with 179 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 08 May 2026 · Interim Dividend - Rs. 1.2
  • 31 Oct 2025 · Interim Dividend - Rs. 0.8
  • 09 May 2025 · Interim Dividend - Rs. 0.8
  • 06 Nov 2024 · Interim Dividend - Rs. 0.4
  • 08 May 2024 · Interim Dividend - Rs. 0.4
  • 02 Nov 2023 · Interim Dividend - Rs. 0.4

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.